Monopar Therapeutics (NASDAQ:MNPR) Issues Quarterly Earnings Results, Beats Estimates By $0.10 EPS

Monopar Therapeutics (NASDAQ:MNPR) released its quarterly earnings data on Thursday. The company reported ($0.72) EPS for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.10, FiscalAI reports.

Monopar Therapeutics Stock Up 1.3%

NASDAQ MNPR traded up $0.95 during trading hours on Thursday, hitting $72.68. The company had a trading volume of 313,027 shares, compared to its average volume of 203,336. Monopar Therapeutics has a fifty-two week low of $50.07 and a fifty-two week high of $124.82. The business has a fifty day simple moving average of $84.40 and a 200-day simple moving average of $77.39. The firm has a market cap of $487.83 million, a P/E ratio of -33.49 and a beta of 1.62.

Insider Buying and Selling

In other news, Director Kim R. Tsuchimoto sold 2,891 shares of the company’s stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $71.26, for a total transaction of $206,012.66. Following the completion of the transaction, the director owned 1,199 shares in the company, valued at approximately $85,440.74. This represents a 70.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Raymond Anderson sold 3,142 shares of the company’s stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $68.35, for a total transaction of $214,755.70. Following the transaction, the director owned 5,373 shares of the company’s stock, valued at $367,244.55. This represents a 36.90% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 51,920 shares of company stock valued at $4,527,913. 9.70% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on MNPR. Zacks Research downgraded shares of Monopar Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 13th. Cantor Fitzgerald raised shares of Monopar Therapeutics from a “neutral” rating to an “overweight” rating and set a $119.00 price objective for the company in a research report on Thursday. Morgan Stanley reiterated an “overweight” rating and set a $130.00 price objective on shares of Monopar Therapeutics in a research note on Monday, August 17th. Wall Street Zen cut shares of Monopar Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, October 10th. Finally, BTIG Research restated a “buy” rating on shares of Monopar Therapeutics in a research note on Thursday. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $122.78.

About Monopar Therapeutics

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. Its pipeline includes radiopharmaceutical candidates designed to target the urokinase plasminogen activator receptor (uPAR), a protein found at elevated levels in some cancers. The company is developing MNPR-101-Zr as an imaging agent to identify uPAR-expressing tumors and MNPR-101-Lu as a potential targeted radiation therapy. These candidates are investigational and are not approved for commercial use.